Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. [electronic resource]
Producer: 20201207Description: 660-665 p. digitalISSN:- 1600-0641
- Antiviral Agents -- administration & dosage
- Carbamates -- administration & dosage
- Drug Combinations
- Drug Monitoring -- methods
- Female
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- complications
- Heterocyclic Compounds, 4 or More Rings -- administration & dosage
- Humans
- Kidney Failure, Chronic -- complications
- Liver Cirrhosis -- diagnosis
- Male
- Middle Aged
- Renal Dialysis -- methods
- Sofosbuvir -- administration & dosage
- Sustained Virologic Response
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.